As of February, 20 Genmab A/S (GNMSF) Analysts See $1.76 EPS

Genmab A/S (OTCMKTS:GNMSF) Corporate Logo

Genmab A/S (OTCMKTS:GNMSF)’s quarterly earnings will be reported on February, 20., as reported by RTT. GNMSF’s profit could be $110.11 million with 20.88 P/E in case $1.76 EPS is reported. The last price was $147.It’s since February 14, 2018 and is 0.00% down. The stock the S&P500 by 0.00%.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark.The firm is valued at $9.20 billion. The firm markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma ; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).40.99 is the P/E ratio. The Company’s products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies.

For more Genmab A/S (OTCMKTS:GNMSF) news posted briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Genmab’s ofatumumab flunks late-stage NHL study – Seeking Alpha” posted on May 24, 2018, “J & J’s Darzalex successful in late-stage study in first-line multiple myeloma – Seeking Alpha” on October 30, 2018, “Genmab chief says cancer med Darzalex could achieve peak sales of $9B – Seeking Alpha” with a publish date: February 22, 2017, “Genmab A/S 2018 Q1 – Results – Earnings Call Slides – Seeking Alpha” and the last “Danish Biotech Genmab Designed Johnson & Johnson’s Fastest-Growing Drug – Seeking Alpha” with publication date: April 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.